Pfizer's COVID product sales to top $50 bln this year, investors want more

Pfizer Inc said on Tuesday it expects 2022 sales of its COVID-19 vaccine and antiviral pill to top $54 billion, but that fell short of lofty Wall Street estimates and its shares were off about 3%. Still, Chief Executive Albert Bourla said final sales for its oral COVID-19 antiviral, Paxlovid, could be 'way bigger' than what Pfizer has forecast since its current outlook only included contracts that have been or are close to being signed. Pfizer currently expects $22 billion in 2022 sales of the treatment, compared with Wall Street estimates of $22.88 billion.